A Multicenter, Open-Label Study to Investigate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Children (≥ 4 to < 17 Years of Age) With Epilepsy
Phase of Trial: Phase II/III
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Lacosamide (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB
- 16 Jul 2018 Planned End Date changed from 1 Aug 2020 to 1 Jun 2020.
- 16 Jul 2018 Planned primary completion date changed from 1 Aug 2020 to 1 Jun 2020.
- 24 Jun 2018 This trial has been completed in Germany